DDInter1328 DDInter1376
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Olaratumab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Olaratumab may lead to a major life threatening interaction when taken with Leflunomide